-
ITCI Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Intra-Cellular Therapies (ITCI)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 308.70 mm | 308.70 mm | 308.70 mm | 308.70 mm | 308.70 mm | 308.70 mm |
Cash burn (monthly) | 52.45 mm | (no burn) | 9.73 mm | 9.73 mm | 4.36 mm | 6.10 mm |
Cash used (since last report) | 109.14 mm | n/a | 20.25 mm | 20.24 mm | 9.07 mm | 12.69 mm |
Cash remaining | 199.56 mm | n/a | 288.45 mm | 288.46 mm | 299.63 mm | 296.01 mm |
Runway (months of cash) | 3.8 | n/a | 29.6 | 29.7 | 68.7 | 48.5 |
13F holders | Current |
---|---|
Total holders | 380 |
Opened positions | 70 |
Closed positions | 38 |
Increased positions | 129 |
Reduced positions | 134 |
13F shares | Current |
---|---|
Total value | 7.76 tn |
Total shares | 99.95 mm |
Total puts | 104.80 k |
Total calls | 283.40 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 11.08 mm | $925.10 bn |
Vanguard | 9.72 mm | $811.93 bn |
BlackRock | 6.11 mm | $510.53 bn |
JPM JPMorgan Chase & Co. | 5.13 mm | $428.13 bn |
BBBOF BB Biotech | 3.54 mm | $112.52 mm |
Wasatch Advisors | 3.25 mm | $271.34 bn |
Norges Bank | 3.21 mm | $268.35 bn |
IVZ Invesco | 3.08 mm | $257.01 bn |
Avoro Capital Advisors | 3.05 mm | $254.74 bn |
BLVGF Bellevue | 2.44 mm | $203.81 bn |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Feb 25 | Marcus Joel S | Common Stock | Option exercise | Acquire M | No | No | 63.79 | 7,009 | 447.10 k | 48,238 |
24 Feb 25 | Marcus Joel S | Stock Option Common Stock | Option exercise | Dispose M | No | No | 63.79 | 7,009 | 447.10 k | 0 |
3 Feb 25 | Sanjeev Narula | RSU Common Stock | Grant | Acquire A | No | No | 0 | 22,727 | 0.00 | 22,727 |
3 Feb 25 | Suresh K. Durgam | RSU Common Stock | Grant | Acquire A | No | No | 0 | 24,621 | 0.00 | 24,621 |
3 Feb 25 | Michael Halstead | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,454 | 0.00 | 45,454 |
3 Feb 25 | Mark Neumann | RSU Common Stock | Grant | Acquire A | No | No | 0 | 22,727 | 0.00 | 22,727 |
31 Jan 25 | Suresh K. Durgam | Common Stock | Payment of exercise | Dispose F | No | No | 127 | 4,730 | 600.71 k | 26,090 |
31 Jan 25 | Suresh K. Durgam | Common Stock | Grant | Acquire A | No | No | 0 | 11,017 | 0.00 | 30,820 |
31 Jan 25 | Michael Halstead | Common Stock | Payment of exercise | Dispose F | No | No | 127 | 5,691 | 722.76 k | 5,326 |
31 Jan 25 | Michael Halstead | Common Stock | Grant | Acquire A | No | No | 0 | 11,017 | 0.00 | 11,017 |